Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

Completed · Phase 4

Conditions studied: Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality

In brief

Study to determine the safety and appropriate dosage of OPTISON in pediatric participants since OPTISON has been tested in adult participants only during the clinical development

Key facts

Study ID

NCT03740997

Run by

GE Healthcare

People needed

39

Starts

2020-12-01

Expected to finish

2023-03-30

Last updated by the study team

2024-05-17

Who can join

Age: 9 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant was between ≥9 and <18 years of age and weighs ≥20 kg.
• The participant was clinically indicated to undergo a transthoracic echocardiogram.
• The participant had a suboptimal non-contrast echocardiogram defined as ≥2 contiguous segments in any given view that cannot be visualized.
• The participant was able to comply with study procedures.
• A parent or legal guardian of the participant had signed and dated an informed consent form.
• Post-menarchal female participants must have had a negative urine pregnancy test at screening and at pre-dose on the day of OPTISON administration.
• Post-menarchal female participants must have been practicing abstinence, or be using an effective form of birth control (e.g., intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or consort use of condom) for at least 30 days before being enrolled in the study

You may not qualify if…

• The participant was previously enrolled in this study.
• The participant received an investigational medicinal product within 30 days before or is scheduled to receive one from time of entry into this study until completion of the follow-up period proposed for this study.
• The participant had a known or suspected hypersensitivity to any of the components of OPTISON, blood, blood products, or albumin.
• The participant had pulmonary hypertension or unstable cardiopulmonary conditions.
• The participant had severe liver disease based on medical history.
• The participant had a recent (<6 months) neurological event.
• The participant presented any clinically active, serious, life-threatening disease, with a life expectancy of less than 1 month or where study participation may compromise the management of the participant or other reason that in the judgment of the investigator makes the participant unsuitable for participation in the study.
• The participant was a pregnant or lactating female, or was a female of childbearing potential not using an acceptable form of birth control (negative urine pregnancy test was also required).

Where it is running

• Phoenix Children's Hospital — Phoenix, Arizona, United States
• Children's Hospital Los Angeles — Los Angeles, California, United States
• MCG Health, Inc. — Augusta, Georgia, United States
• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
• Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
• Cohen Children's Medical Center of New York — Lake Success, New York, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.